Grufity logo
Grufity logo
ATOS

ATOS - Atossa Genetics Inc Stock Price, Fair Value and News

$2.22-0.13 (-5.53%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

Price Targets

ATOS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ATOS Price Action

Last 7 days

-47.9%

Last 30 days

-51.1%

Last 90 days

-56.8%

Trailing 12 Months

-81.0%

ATOS RSI Chart

ATOS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ATOS Valuation

Market Cap

19.1M

Price/Earnings (Trailing)

-0.51

Price/Sales (Trailing)

532.12

EV/EBITDA

0.33

Price/Free Cashflow

-0.57

ATOS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

ATOS Fundamentals

ATOS Revenue

Revenue (TTM)

84.6K

ATOS Earnings

Earnings (TTM)

-37.6M

Earnings Growth (Yr)

-42.74%

Earnings Growth (Qtr)

12.33%

ATOS Profitability

Operating Margin

1752.83%

EBT Margin

-44472.93%

Return on Equity

-123.47%

Return on Assets

-99.2%

Free Cashflow Yield

-174.9%

ATOS Investor Care

Shares Dilution (1Y)

0.00%

Diluted EPS (TTM)

-4.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2015----
2014474.0K157.8K84.6K-
2013609.8K712.8K683.8K632.6K
2012---481.8K
2011----
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Atossa Genetics Inc

ATOS
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
 CEO
 WEBSITEhttps://atossatherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES11

Atossa Genetics Inc Frequently Asked Questions

ATOS is the stock ticker symbol of Atossa Genetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Atossa Genetics Inc is 20.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, ATOS's PE ratio (Price to Earnings) is -0.54 and Price to Sales (PS) ratio is 532.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATOS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Atossa Genetics Inc has provided -0.44 (multiply by 100 for percentage) rate of return.